Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals’ share price has reached an all-time high following results from its EmtinB treatment for neurodegenerative diseases like Alzheimer’s and Parkinson’s
  • The EmtinB treatment focusses on regenerating damaged neurons, and represents the first time ever this type of model has been effective in treating neurodegenerative diseases
  • EmtinB caused significant regeneration of nerve cells by twice as much as leading marketed Multiple Sclerosis drug Copaxon, which has reached peak annual sales of $4 billion
  • NeuroScientific Biopharmaceuticals shares soar 120.69 per cent as at 11:52 AEST, trading for 32 cents a piece

NeuroScientific Biopharmaceuticals has seen share prices skyrocket to an all-time high today following breakthrough results from its EmtinB treatment.

According to NeutoScientific, this study paves the way for breakthrough treatments in Alzheimer’s disease. The EmtinB treatment focusses on regenerating damaged neurons, meaning it also has applications in effectively treating other neurodegenerative diseases like Parkinson’s, Multiple Sclerosis and more.

Neurons are nerve cells that send and receive information inside of the central nervous system and are generally known as the core working units of the human brain. As we age, however, our neurons can gradually become damaged and fail to work as effectively as they should — resulting in neurodegenerative diseases like Alzheimer’s.

Normally, a damaged neuron can’t repair, reproduce or replace itself in the body; once it’s damaged, it’s damaged for good. This is where EmtinB comes in. NeuroScientific’s breakthrough treatment is an artificially manufactured molecule, known as a ‘peptide dendrimer’, which essentially connects itself to a damaged neutron and causes it to start regenerating itself.

In the company’s recent study, EmtinB caused significant regeneration of nerve cells by twice as much as leading marketed Multiple Sclerosis drug Copaxon, which has reached peak annual sales of $4 billion.

The study was designed to test primary nerve cells isolated from adult rat spinal cord tissue. This is the first time a dendrimer type molecule targeting the cell survival pathway has been effective in treating neurodegenerative diseases.

NeuroScientific CEO Matthew Liddelow said the results from the study far exceeded expectations in every test.

“We could finally have a disease modifying therapy for Alzheimer’s,” Matthew said.

Chairman Brian Leedman added that as it stands there are no approved drugs able to slow down or stop neurodegeneration.

“We believe that EmtinB has potential to bridge this gap and bring this breakthrough medicine to clinics and with our strong cash position, look forward to commencing our human studies,” Brian said.

NSB shares rose over 150 per cent this morning following the release of the study results. The have since dropped slightly, but still trade at an all time high of $0.32 each — a 120.69 per cent increase on the company’s last closing price.

NSB by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug